within Pharmacolibrary.Drugs.ATC.L;

model L01CB01_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 15.0,            
    Vdp             = 0.0039,
    k12             = 5.0,
    k21             = 5.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CB01_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Etoposide is a topoisomerase II inhibitor used as an antineoplastic agent for the treatment of various malignancies including small-cell lung cancer, testicular cancer, lymphoma, and leukemia. It is commonly administered intravenously or orally and is still approved and widely used in cancer chemotherapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported after oral administration in adult patients with cancer.</p><h4>References</h4><ol><li><p>Phillips, NC (1988). Oral etoposide. <i>Drug intelligence &amp; clinical pharmacy</i> 22(11) 860–863. DOI:<a href=&quot;https://doi.org/10.1177/106002808802201103&quot;>10.1177/106002808802201103</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3069425/&quot;>https://pubmed.ncbi.nlm.nih.gov/3069425</a></p></li><li><p>Wilson, WH, et al., &amp; Balis, F (2002). Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i> 99(8) 2685–2693. DOI:<a href=&quot;https://doi.org/10.1182/blood.v99.8.2685&quot;>10.1182/blood.v99.8.2685</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11929754/&quot;>https://pubmed.ncbi.nlm.nih.gov/11929754</a></p></li><li><p>Aita, P, et al., &amp; Toffoli, G (1999). Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. <i>Cancer chemotherapy and pharmacology</i> 43(4) 287–294. DOI:<a href=&quot;https://doi.org/10.1007/s002800050897&quot;>10.1007/s002800050897</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10071979/&quot;>https://pubmed.ncbi.nlm.nih.gov/10071979</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CB01_1;
